Inovio’s Phase II/III COVID-19 vaccine study delayed pending resolution of partial hold, funding

FDA’s partial hold on Inovio’s planned Phase II/III COVID-19 vaccine trial comes as the company is seeking additional funding to support the study. 

Inovio Pharmaceuticals Inc. (NASDAQ:INO) fell $4.80 (28%) to $12.14 Monday, losing $804 million in market value, after revealing that FDA has additional questions regarding the planned trial of INO-4800 and its Cellectra device for delivering the DNA vaccine. ...